Loading
Gabather AB Stock: price and insider trades · Sweden
Gabather AB: what insiders have been doing
Only a handful of insider records exist for Gabather AB, the last one from 2 December 2025, too few to describe a trend. This summary is built from Finansinspektionen disclosures alone and does not predict where the share price will go.
Insider Decl.
1
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Financial data
as of FY 2025FY ended December 2025 · cache
SEK 0.03
Analyst consensus
Income statement
EBITDA-SEK 4.5M
Net income-SEK 4.7M0.0% margin
Valuation
P/Book6.2x
Beta-0.77
Balance sheet & cash
Market capSEK 18.8M
Free Cash Flow-SEK 7.2M
Profitability & ownership
ROE-336.9%
ROA-51.3%
% insiders11.2%
% institutions4.5%
Last declaration on 2 December 2025
Declarations1 total
8,562,330 shares@ SEK 0.0251.15% mcap100.0% of flowAktieISIN SE0010869552FI:A003U294-2
1 of 1 declaration
About Gabather AB
Gabather AB is a Swedish pharmaceutical company focused on developing treatments for neurological disorders. It is listed on the Stockholm Stock Exchange (XSTO).
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
